Qure.ai Receives Strategic Investment from Merck to Advance AI-augmented Imaging Solutions
Qure.ai is a leader in deploying AI to enhance diagnostic accuracy and patient outcomes in the medical imaging field.
Company Name: Qure.ai
Location: New York City, NY
Sector: Healthcare, Artificial Intelligence
Funding Details: Received an undisclosed investment from Merck Global Health Innovation Fund as part of its Series D round.
Purpose of Investment: To invest in foundation models for AI in imaging and expand the geographical reach of its AI-powered imaging solutions into the US market.
Leadership: Led by CEO Prashant Warier.
Product: Qure.ai specializes in AI-augmented detection for major health issues such as Tuberculosis (TB), Lung Cancer, and Stroke. The company's offerings include:
- qXR-LN: An FDA-approved AI-powered chest X-ray lung nodule detection solution.
- qSpot-TB: A device with designation for TB solution.
- qER-Suite: An AI-enabled head CT tool for rapid detection, triage, and quantification of traumatic brain injuries and stroke.
- Additional AI solutions for various plain film X-ray emergency room findings.
About Company: Qure.ai is a leader in deploying AI to enhance diagnostic accuracy and patient outcomes in the medical imaging field. Operating at over 2700 imaging sites across more than 90 countries, Qure.ai is expanding its innovative solutions to meet global healthcare challenges, with a focus on entering the US market and enhancing its AI technology foundation. This ongoing partnership with Merck underscores its pivotal role in transforming healthcare through AI.